Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
From The BioCentury Show · · 36 min
This plays from the publisher's own server. We do not host a copy.
Description
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.” In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact. As it approaches its tenth anniversary, the institute has deployed about $400 million (https://www.biocentury.com/article/659073), catalyzing roughly $4 billion in follow-on investment across 17 companies.
View full story: https://www.biocentury.com/article/659476
#CancerImmunotherapy #TranslationalScience #DrugDevelopment #Biopharma #CancerResearch
00:00 - Introduction 01:34 - Optimizing Translation 07:42 - Training the Immune System 16:33 - China’s Opportunity 20:50 - Need for a Cancer Strategy 24:40 - Enhancing Cancer Survivorship 27:55 - Scientific Foundation Under Threat